Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
Tyler WalburnMing-Hui ChenMarian LoffredoElizabeth McMahonPeter F OrioPaul L NguyenAnthony V D'AmicoMutlay SayanPublished in: Cancer (2024)
Docetaxel combined with radiotherapy has an acceptable long-term toxicity profile.